A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Psoriatic Arthritis

Interventions

DRUG: Deucravacitinib
OTHER: Placebo

Sponsor

Bristol-Myers Squibb